Life sciences firms seek validated AI for decision-making, ISG says
III•Life sciences companies are adopting AI to accelerate decisions, but legacy platforms, fragmented data and inconsistent semantics limit reliable deployment at scale, an ISG report finds.
1. AI adoption challenges
Life sciences companies are adopting AI to accelerate decisions as development costs rise, clinical attrition persists and patents expire. The report says legacy platforms, fragmented data and inconsistent semantics limit deployment at scale and reduce output reliability.
2. Demand for validation
Buyers favor AI embedded in scientific workflows with transparent evidence and expert validation. Bounded workflows that preserve expert accountability are in demand as companies move from demonstrations to measurable production results, while managed, transaction-based and outcome-linked sourcing arrangements are expanding.
